{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-24-000004","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.614858+00:00","generated_at":"2026-06-05T09:20:04.805081+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nautilus Biotechnology reports FY2023 net loss $63.7M; cash runway into H2 2026","bullets":["Net loss $63.7M for FY2023, compared to $57.9M in FY2022; operating expenses $76.2M, up 20% YoY.","Cash, equivalents and investments $264.1M as of Dec 31, 2023; expected runway into second half 2026.","FY2024 operating expense expected to grow ~25% vs 2023.","Platform launch (instruments, consumables, software) planned for 2025.","CEO Sujal Patel cited fiscal discipline and progress on proprietary proteome analysis platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-24-000004","json":"https://secwatch.observer/filing/0001808805-24-000004.json","markdown":"https://secwatch.observer/filing/0001808805-24-000004.md","text":"https://secwatch.observer/filing/0001808805-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000004/0001808805-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000004/naut-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:20:04.805081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15af89b560bc349922bb2ce585fc4ef4dc493622","claim":"Nautilus Biotechnology, Inc. updated its Fiscal Year 2024 Outlook guidance (initiated).","evidence_excerpt":"Fiscal Year 2024 Outlook • We expect full year operating expense to grow by approximately 25% relative to 2023 • We expect that cash and cash equivalents and investments of $264.1 million as of December 31, 2023 to provide a runway into the second half of 2026 • We expect to launch our platform, instruments, consumables, and software in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000004/0001808805-24-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fiscal Year 2024 Outlook"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"fc2857db0286ed554e36ca6d470e7dcb7db57f94","claim":"Nautilus Biotechnology, Inc. reported the fiscal year ended December 31, 2023 results: net income $63.7 million.","evidence_excerpt":"Net loss was $63.7 million for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000004/0001808805-24-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Net income","value":"$63.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}